Kim and Abramson Dutton JJ, Anderson RL, Tse DT. 1984. Combined surgery and cryotherapy for scleral invasion of epithelial malignancies. Ophthalmic Surg, 15:289–94. Elkon D, Constable WC. 1979. The use of strontium-90 in the treatment of carcinoma in situ of the conjunctiva. Am J Ophthalmol, 87:84–6. Erie JC, Campbell RJ, Liesegang TJ. 1986. Conjunctival and corneal intraepithelial and invasive neoplasia. Ophthalmology, 93:176–83. Fenton S, Kennedy S, Moriarty P. 2002. The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids. Acta Ophthalmol Scand, 80:674–5. Ferry AP, Meltzer MA, Taub RN. 1976. Immunotherapy with dinitrochlo- robenzene (DNCB) for recurrent squamous cell tumor of conjunctiva. Trans Am Ophthalmol Soc, 74:154–71. Finger PT, Milner MS, McCormick SA. 1993. Topical chemotherapy for conjunctival melanoma. Br J Ophthalmol, 77:751–3. Folberg R, McLean IW, Zimmerman LE. 1984. Conjunctival melanosis and melanoma. Ophthalmology, 91:673–8. Folberg R, McLean IW, Zimmerman LE. 1985a. Malignant melanoma of the conjunctiva. Hum Pathol, 16:136–43. Folberg R, McLean IW, Zimmerman LE. 1985b. Primary acquired melanosis of the conjunctiva. Hum Pathol, 16:129–35. Frucht-Pery J, Ilsar M. 1994. The use of low-dose mitomycin C for preven- tion of recurrent pterygium. Ophthalmology, 101:759–62. Frucht-Pery J, Pe’er J. 1996. Use of mitomycin C in the treatment of con- junctival primary acquired melanosis with atypia. Arch Ophthalmol, 114:1261–4. Frucht-Pery J, Rozenman Y, Pe’er J. 2002. Topical mitomycin-C for par- tially excised conjunctival squamous cell carcinoma. Ophthalmology, 109:548–52. Frucht-Pery J, Sugar J, Baum J, et al. 1997. Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience. Ophthalmology, 104:2085–93. Goldberg JR, Becker SC, Rosenbaum HD. 1963. Gamma radiation in the treatment of squamous-cell carcinoma of the limbus. Am J Ophthalmol, 55: 811–15. Heigle TJ, Stulting RD, Palay DA. 1997. Treatment of recurrent conjunc- tival epithelial neoplasia with topical mitomycin C. Am J Ophthalmol, 124:397–9. Jakobiec FA, Folberg R, Iwamoto T. 1989. Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology, 96:147–66. Jones DB, Wilhelmus KR, Font RL. 1991. Beta radiation of recurrent cor- neal intraepithelial neoplasia. Trans Am Ophthalmol Soc, 89:285–98; discussion 298–301. Karcioglu ZA, Issa TM. 1997. Human papilloma virus in neoplastic and non-neoplastic conditions of the external eye. Br J Ophthalmol, 81:595–8. Karp CL, Moore JK, Rosa RH. 2001. Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Ophthalmology, 108:1093–8. Kass LG, Hornblass A. 1989. Sebaceous carcinoma of the ocular adnexa. Surv Ophthalmol, 33:477–90. Katz GJ, Higginbotham EJ, Lichter PR, et al. 1995. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Ophthalmology, 102:1263–9. Kemp EG, Harnett AN, Chatterjee S. 2002. Preoperative topical and intra- operative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias. Br J Ophthalmol, 86:31–4. Khong JJ, Muecke J. 2006. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol, 90:819–22. Kobayashi A, Yoshita T, Uchiyama K, et al. 2002. Successful management of conjunctival intraepithelial neoplasia by interferon alpha-2b. Jpn J Ophthalmol, 46:215–17. Kurli M, Finger PT. 2005. Topical mitomycin chemotherapy for con- junctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience. Graefes Arch Clin Exp Ophthalmol, 243:1108–14. 514 Lee GA, Hirst LW. 1995. Ocular surface squamous neoplasia. Surv Ophthalmol, 39:429–50. Liesegang TJ, Campbell RJ. 1980. Mayo Clinic experience with conjunctival melanomas. Arch Ophthalmol, 98:1385–9. Maskin SL. 1994. Regression of limbal epithelial dysplasia with topical interferon. Arch Ophthalmol, 112:1145–6. McKelvie PA, Daniell M. 2001. Impression cytology following mitomycin C therapy for ocular surface squamous neoplasia. Br J Ophthalmol, 85:1115–19. Midena E, Angeli CD, Valenti M, et al. 2000. Treatment of conjunctival squamous cell carcinoma with topical 5-ﬂuorouracil. Br J Ophthalmol, 84:268–72. Murphy WM, Soloway MS, Finebaum PJ. 1981. Pathological changes associated with topical chemotherapy for superﬁcial bladder cancer. J Urol, 126:461–4. Nadjari B, Kersten A, Ross B, et al. 1999. Cytologic and DNA cytometric diagnosis and therapy monitoring of squamous cell carcinoma in situ and malignant melanoma of the cornea and conjunctiva. Anal Quant Cytol Histol, 21:387–96. Palmer SS. 1991. Mitomycin as adjunct chemotherapy with trabeculectomy. Ophthalmology, 98:317–21. Paridaens AD, McCartney AC, Minassian DC, et al. 1994. Orbital exen- teration in 95 cases of primary conjunctival malignant melanoma. Br J Ophthalmol, 78:520–8. Paridaens AD, Minassian DC, McCartney AC, et al. 1994. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathologi- cal study of 256 cases. Br J Ophthalmol, 78:252–9. Pe’er J, Frucht-Pery J. 2005. The treatment of primary acquired melano- sis (PAM) with atypia by topical Mitomycin C. Am J Ophthalmol, 139:229–34. Peksayar G, Soyturk MK, Demiryont M. 1989. Long-term results of cryotherapy on malignant epithelial tumors of the conjunctiva. Am J Ophthalmol, 107:337–40. Pizzarello LD, Jakobiec FA. 1978. Bowen’s disease of the conjunctiva: a misnomer. Birmingham, AL, Aesculapius. Prabhasawat P, Tarinvorakup P, Tesavibul N, et al. 2005. Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea, 24:443–8. Putterman AM. 1986. Conjunctival map biopsy to determine pagetoid spread. Am J Ophthalmol, 102:87–90. Rodriguez-Ares T, Tourino R, De Rojas V, et al. 2003. Topical mitomy- cin C in the treatment of pigmented conjunctival lesions. Cornea, 22:114–17. Rozenman Y, Frucht-Pery J. 2000. Treatment of conjunctival intraepithelial neoplasia with topical drops of mitomycin C. Cornea, 19:1–6. Sacu S, Segur-Eltz N, Horvat R, et al. 2003. Intumescent cataract after topical mitomycin-C for conjunctival malignant melanoma. Am J Ophthalmol, 136:375–7. Salomao DR, Mathers WD, Sutphin JE, et al. 1999. Cytologic changes in the conjunctiva mimicking malignancy after topical mitomycin C chemotherapy. Ophthalmology, 106:1756–60; discussion, 1761. Schechter BA, Schrier A, Nagler RS, et al. 2002. Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Cornea, 21:6–11. Scott IU, Karp CL, Nuovo GJ. 2002. Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia. Ophthalmology, 109:542–7. Seregard S. 1998. Conjunctival melanoma. Surv Ophthalmol, 42:321–50. Seregard S, Kock E. 1992. Conjunctival malignant melanoma in Sweden 1969–91. Acta Ophthalmol (Copenh), 70:289–96. Shapiro MS, Thoft RA, Friend J, et al. 1985. 5-Fluorouracil toxicity to the ocular surface epithelium. Invest Ophthalmol Vis Sci, 26:580–3. Shields CL, Demirci H, Marr BP, et al. 2005. Chemoreduction with topical mitomycin C prior to resection of extensive squamous cell carcinoma of the conjunctiva. Arch Ophthalmol, 123:109–13. Shields CL, Naseripour M, Shields JA, et al. 2002. Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol, 133:601–6. Clinical Ophthalmology 2008:2(3)